Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/15/2025

Risankizumab Treatment Protocol for Chronic Plaque Psoriasis

Dosing and Administration

  • The American Academy of Dermatology recommends a standard dosing regimen of 150 mg subcutaneously at weeks 0 and 4, then every 12 weeks thereafter, for the treatment of moderate-to-severe chronic plaque psoriasis 1
  • Maintenance dosing of 150 mg every 12 weeks thereafter is recommended for patients with chronic plaque psoriasis 1

Efficacy Benchmarks

  • The American Academy of Dermatology reports that 36-45% of patients achieve PASI 100 at week 16 when treated with risankizumab 2

Response Assessment Timeline

  • Assess treatment response at 12 weeks of continuous therapy to determine definitive positive or negative response, as recommended by the American Academy of Dermatology 3
  • For partial responders at 12 weeks, consider adding topical corticosteroids, vitamin D analogues, methotrexate, or ultraviolet B phototherapy, as suggested by the American Academy of Dermatology 3

Special Populations and Considerations

  • Use caution in patients with pre-existing immunosuppression-related conditions, as recommended by the American Academy of Dermatology 2, 3
  • Ensure prophylactic vaccination against pneumococcal and influenza infections before initiating therapy, as recommended by the American Academy of Dermatology 4

Safety Monitoring

  • Screen for active infections, tuberculosis, and malignancy at baseline, as recommended by the American Academy of Dermatology 2
  • Establish baseline respiratory status if respiratory comorbidities are present, as recommended by the American Academy of Dermatology 4
  • Complete indicated vaccinations, as recommended by the American Academy of Dermatology 1

Treatment Interruption and Resumption

  • Discontinue risankizumab approximately 3-4 half-lives before elective surgery, as recommended by the American Academy of Dermatology 1
  • Resume risankizumab 1-2 weeks after surgery if no postoperative complications, as recommended by the American Academy of Dermatology 1

Comparative Positioning

  • Risankizumab demonstrates superior efficacy compared to ustekinumab, with 75% vs 42% achieving PASI 90 at week 12, as reported by the American Academy of Dermatology 2

Risankizumab Therapy for Moderate to Severe Plaque Psoriasis

Safety Considerations

  • The American Academy of Dermatology recommends using caution in patients with pre-existing immunosuppression-related conditions and active infections, which may require temporary discontinuation of risankizumab therapy 5

Pharmacokinetic Properties

  • The bioavailability of risankizumab is 89% following subcutaneous administration, with a time to peak concentration of 3-14 days after dosing, and a terminal half-life of approximately 28 days, as reported by the Journal of the American Academy of Dermatology 5